| Year |
Citation |
Score |
| 2022 |
Huang Z, Rockhold FW, Jones WS, Hernandez AF, McCall D, DeMets DL, Hochman JS, Gersh BJ, Campos H, Jacobs AK, Yancy CW. The challenges of data safety monitoring for a pragmatic study: Lessons from the ADAPTABLE study. Contemporary Clinical Trials. 106732. PMID 35301133 DOI: 10.1016/j.cct.2022.106732 |
0.31 |
|
| 2020 |
Docherty KF, Jhund PS, Bengtsson O, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Sabatine MS, Sjöstrand M, Solomon SD, McMurray JJV. Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. Diabetes Care. 43: 2878-2881. PMID 33082245 DOI: 10.2337/Dc20-1402 |
0.332 |
|
| 2020 |
Docherty KF, Jhund PS, Anand I, Bengtsson O, Böhm M, de Boer RA, DeMets DL, Desai AS, Drozdz J, Howlett J, Inzucchi SE, Johanson P, Katova T, Køber L, Kosiborod MN, et al. Effect of Dapagliflozin on Outpatient Worsening of Patients with Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF. Circulation. PMID 32883108 DOI: 10.1161/Circulationaha.120.047480 |
0.345 |
|
| 2020 |
Serenelli M, Böhm M, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, DeMets DL, Bengtsson O, Sjöstrand M, Langkilde AM, Anand IS, Chiang CE, et al. Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). European Heart Journal. PMID 32820334 DOI: 10.1093/Eurheartj/Ehaa496 |
0.342 |
|
| 2020 |
Jackson AM, Dewan P, Anand IS, Bělohlávek J, Bengtsson O, de Boer RA, Böhm M, Boulton DW, Chopra VK, Demets DL, Docherty KF, Dukát A, Greasley PJ, Howlett JG, Inzucchi SE, et al. Dapagliflozin and Diuretic Use in Patients with Heart Failure and Reduced Ejection Fraction in DAPA-HF. Circulation. PMID 32673497 DOI: 10.1161/Circulationaha.120.047077 |
0.361 |
|
| 2020 |
DeMets DL, Fleming TR. Achieving Effective Informed Oversight by DMCs in COVID Clinical Trials. Journal of Clinical Epidemiology. PMID 32659363 DOI: 10.1016/J.Jclinepi.2020.07.001 |
0.418 |
|
| 2020 |
Dewan P, Solomon SD, Jhund PS, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, DeMets DL, Sabatine MS, Bengtsson O, Sjöstrand M, Langkilde AM, Anand IS, Bělohlávek J, et al. Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF. European Journal of Heart Failure. PMID 32539224 DOI: 10.1002/Ejhf.1867 |
0.322 |
|
| 2020 |
Brenner J, LeBlang S, Lizotte-Waniewski M, Schmidt B, Espinosa PS, DeMets DL, Newberg A, Hennekens CH. Mindfulness with paced breathing reduces blood pressure. Medical Hypotheses. 142: 109780. PMID 32353795 DOI: 10.1016/J.Mehy.2020.109780 |
0.335 |
|
| 2020 |
Docherty KF, Jhund PS, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, DeMets DL, Sabatine MS, Bengtsson O, Sjöstrand M, Langkilde AM, Desai AS, Diez M, Howlett JG, et al. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. European Heart Journal. PMID 32221582 DOI: 10.1093/Eurheartj/Ehaa183 |
0.319 |
|
| 2020 |
Acharya A, Glurich I, Hetzel S, Kim K, Tattersall MC, DeMets DL, Hennekens CH. Correlation between Oral Health and Systemic Inflammation (COHESION): A Randomized Pilot Follow Up Trial of a Plaque Identifying Toothpaste. The American Journal of Medicine. PMID 32105658 DOI: 10.1016/J.Amjmed.2020.01.023 |
0.311 |
|
| 2019 |
Kosiborod MN, Jhund P, Docherty KF, Diez M, Petrie MC, Verma S, Nicolau JC, Merkely B, Kitakaze M, DeMets DL, Inzucchi SE, Køeber L, Martinez FA, Ponikowski P, Sabatine MS, et al. Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients with Heart Failure and Reduced Ejection Fraction: Results from the DAPA-HF Trial. Circulation. PMID 31736335 DOI: 10.1161/Circulationaha.119.044138 |
0.356 |
|
| 2019 |
Martinez FA, Serenelli M, Nicolau JC, Petrie MC, Chiang CE, Tereshchenko S, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Ponikowski P, Sabatine MS, Demets DL, Dutkiewicz-Piasecka M, Bengtsson O, et al. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF. Circulation. PMID 31736328 DOI: 10.1161/Circulationaha.119.044133 |
0.346 |
|
| 2019 |
McMurray JJV, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD. The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. European Journal of Heart Failure. PMID 31309699 DOI: 10.1002/Ejhf.1548 |
0.367 |
|
| 2019 |
Cairns JA, Eikelboom JW, Shestakovska O, Yusuf S, DeMets D. Monitoring Emerging Data From the COMPASS Trial of an Antithrombotic Agent. Journal of the American College of Cardiology. 73: 2769-2772. PMID 31146821 DOI: 10.1016/J.Jacc.2019.03.479 |
0.414 |
|
| 2019 |
McMurray JJV, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). European Journal of Heart Failure. PMID 30895697 DOI: 10.1002/Ejhf.1432 |
0.339 |
|
| 2018 |
DeMets D. The independent statistician model: How well is it working? Clinical Trials. 15: 329-334. PMID 29741390 DOI: 10.1177/1740774518772841 |
0.389 |
|
| 2018 |
Fleming TR, Ellenberg SS, DeMets DL. Data Monitoring Committees: Current issues. Clinical Trials (London, England). 1740774518764855. PMID 29629815 DOI: 10.1177/1740774518764855 |
0.413 |
|
| 2017 |
Calis KA, Archdeacon P, Bain R, DeMets D, Donohue M, Elzarrad MK, Forrest A, McEachern J, Pencina MJ, Perlmutter J, Lewis RJ. Recommendations for data monitoring committees from the Clinical Trials Transformation Initiative. Clinical Trials (London, England). 1740774517707743. PMID 28503947 DOI: 10.1177/1740774517707743 |
0.399 |
|
| 2017 |
Packer M, Pitt B, Rouleau JL, Swedberg K, DeMets DL, Fisher L. Long-Term Effects of Flosequinan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the PROFILE Trial After 24 Years. Jacc. Heart Failure. PMID 28501522 DOI: 10.1016/J.Jchf.2017.03.003 |
0.349 |
|
| 2017 |
Packer M, McMurray JJV, Krum H, Kiowski W, Massie BM, Caspi A, Pratt CM, Petrie MC, DeMets D, Kobrin I, Roux S, Swedberg K. Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the ENABLE Trials. Jacc. Heart Failure. 5: 317-326. PMID 28449795 DOI: 10.1016/J.Jchf.2017.02.021 |
0.34 |
|
| 2017 |
Fleming TR, DeMets DL, Roe MT, Wittes J, Calis KA, Vora AN, Meisel A, Bain RP, Konstam MA, Pencina MJ, Gordon DJ, Mahaffey KW, Hennekens CH, Neaton JD, Pearson GD, et al. Data monitoring committees: Promoting best practices to address emerging challenges. Clinical Trials (London, England). 14: 115-123. PMID 28359194 DOI: 10.1177/1740774516688915 |
0.358 |
|
| 2017 |
Kalscheur MM, Saxon LA, Lee BK, Steinberg JS, Mei C, Buhr KA, DeMets DL, Bristow MR, Singh SN. Outcomes of Cardiac Resynchronization Therapy in Patients with Intermittent Atrial Fibrillation or Atrial Flutter in the COMPANION Trial. Heart Rhythm. PMID 28323173 DOI: 10.1016/J.Hrthm.2017.03.024 |
0.33 |
|
| 2016 |
Lewis RJ, Calis KA, DeMets DL. Enhancing the Scientific Integrity and Safety of Clinical Trials: Recommendations for Data Monitoring Committees. Jama. 316: 2359-2360. PMID 27960001 DOI: 10.1001/Jama.2016.16070 |
0.381 |
|
| 2016 |
Calis KA, Archdeacon P, Bain RP, Forrest A, Perlmutter J, DeMets DL. Understanding the functions and operations of data monitoring committees: Survey and focus group findings. Clinical Trials (London, England). PMID 27885056 DOI: 10.1177/1740774516679665 |
0.349 |
|
| 2016 |
Fasula K, Evans CA, Boyd L, Giblin L, Belavsky BZ, Hetzel S, McBride P, DeMets DL, Hennekens CH. Randomized trial of Plaque identifying Toothpaste: Dental Plaque and Inflammation. The American Journal of Medicine. PMID 27771276 DOI: 10.1016/J.Amjmed.2016.09.003 |
0.32 |
|
| 2016 |
DeMets DL, Ellenberg SS. Data Monitoring Committees - Expect the Unexpected. The New England Journal of Medicine. 375: 1365-1371. PMID 27705256 DOI: 10.1056/Nejmra1510066 |
0.422 |
|
| 2016 |
Lo B, DeMets DL. Incentives for Clinical Trialists to Share Data. The New England Journal of Medicine. 375: 1112-5. PMID 27653562 DOI: 10.1056/Nejmp1608351 |
0.314 |
|
| 2016 |
Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, DeMets D, Evans S, Law M, MacMahon S, Martin S, Neal B, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet (London, England). PMID 27616593 DOI: 10.1016/S0140-6736(16)31357-5 |
0.333 |
|
| 2016 |
Bristow MR, Saxon LA, Feldman AM, Mei C, Anderson SA, DeMets DL. Lessons Learned and Insights Gained in the Design, Analysis, and Outcomes of the COMPANION Trial. Jacc. Heart Failure. PMID 27289408 DOI: 10.1016/J.Jchf.2016.02.019 |
0.38 |
|
| 2015 |
Antman EM, Benjamin EJ, Harrington RA, Houser SR, Peterson ED, Bauman MA, Brown N, Bufalino V, Califf RM, Creager MA, Daugherty A, Demets DL, Dennis BP, Ebadollahi S, Jessup M, et al. Acquisition, Analysis, and Sharing of Data in 2015 and Beyond: A Survey of the Landscape: A Conference Report From the American Heart Association Data Summit 2015. Journal of the American Heart Association. 4. PMID 26541391 DOI: 10.1161/Jaha.115.002810 |
0.329 |
|
| 2015 |
Yang F, Stewart M, Ye J, DeMets D. Type 2 diabetes mellitus development programs in the new regulatory environment with cardiovascular safety requirements. Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy. 8: 315-25. PMID 26229496 DOI: 10.2147/Dmso.S84005 |
0.319 |
|
| 2015 |
Fordyce CB, Roe MT, Ahmad T, Libby P, Borer JS, Hiatt WR, Bristow MR, Packer M, Wasserman SM, Braunstein N, Pitt B, DeMets DL, Cooper-Arnold K, Armstrong PW, Berkowitz SD, et al. Cardiovascular drug development: is it dead or just hibernating? Journal of the American College of Cardiology. 65: 1567-82. PMID 25881939 DOI: 10.1016/J.Jacc.2015.03.016 |
0.311 |
|
| 2015 |
DeMets DL, Wittes JT, Geller NL. The Influence of Biostatistics at the National Heart, Lung, and Blood Institute American Statistician. 69: 108-120. DOI: 10.1080/00031305.2015.1035962 |
0.378 |
|
| 2014 |
Fleming TR, Hennekens CH, Pfeffer MA, DeMets DL. Enhancing trial integrity by protecting the independence of data monitoring committees in clinical trials. Journal of Biopharmaceutical Statistics. 24: 968-75. PMID 24926941 DOI: 10.1080/10543406.2014.925719 |
0.409 |
|
| 2013 |
DeMets D, Wittes J, Siegel J. University of Pennsylvania 5th annual conference on statistical issues in clinical trials: emerging statistical issues in biomarker validation (Morning Session). Clinical Trials (London, England). 10: 680-9. PMID 24130200 DOI: 10.1177/1740774513500388 |
0.37 |
|
| 2013 |
Molitor JA, Demets DL. Can large simple trials help us understand when and how to use generic drugs for uncommon diseases? The Journal of Rheumatology. 40: 539-41. PMID 23637373 DOI: 10.3899/Jrheum.130314 |
0.339 |
|
| 2013 |
Hetzel S, DeMets D, Schneider R, Borzak S, Schneider W, Serebruany V, Schröder H, Hennekens CH. Aspirin increases nitric oxide formation in chronic stable coronary disease. Journal of Cardiovascular Pharmacology and Therapeutics. 18: 217-21. PMID 23524841 DOI: 10.1177/1074248413482753 |
0.321 |
|
| 2013 |
DeMets DL. Data monitoring committees: history and their future. Trials. 14: 1-1. DOI: 10.1186/1745-6215-14-S1-I3 |
0.434 |
|
| 2012 |
D'Agostino R, DeMets D, Friedewald W, Goodman S, Witte J, Geller NL. The future of clinical trials: A panel discussion. Statistics in Medicine. 31: 3068-72. PMID 22806631 DOI: 10.1002/Sim.5484 |
0.366 |
|
| 2012 |
DeMets DL. Current development in clinical trials: issues old and new. Statistics in Medicine. 31: 2944-54. PMID 22736410 DOI: 10.1002/Sim.5405 |
0.395 |
|
| 2012 |
Zheng G, Wu CO, Yang S, Waclawiw MA, DeMets DL, Geller NL. NHLBI clinical trials workshop: an executive summary. Statistics in Medicine. 31: 2938-43. PMID 22733431 DOI: 10.1002/Sim.5406 |
0.419 |
|
| 2012 |
Hennekens CH, Hetzel S, Pfeffer M, Schneider R, Borzak S, Schneider W, Serebruany V, DeMets D. Low-dose enteric-coated aspirin does not inhibit thromboxane B2 and prostaglandin E2: data-derived hypothesis formulation Clinical Investigation. 2: 747-752. DOI: 10.4155/Cli.12.56 |
0.305 |
|
| 2012 |
DeMets DL, Friedman L. Some Thoughts on Challenges for Noninferiority Study Designs Drug Information Journal. 46: 420-427. DOI: 10.1177/0092861512445310 |
0.339 |
|
| 2011 |
DeMets DL, Califf RM. A historical perspective on clinical trials innovation and leadership: where have the academics gone? Jama. 305: 713-4. PMID 21325190 DOI: 10.1001/Jama.2011.175 |
0.413 |
|
| 2011 |
Komajda M, Carson PE, Hetzel S, McKelvie R, McMurray J, Ptaszynska A, Zile MR, DeMets D, Massie BM. Factors Associated With Outcome in Heart Failure With Preserved Ejection FractionClinical Perspective Circulation-Heart Failure. 4: 27-35. PMID 21068341 DOI: 10.1161/Circheartfailure.109.932996 |
0.357 |
|
| 2011 |
Hennekens CH, DeMets D. Data and safety monitoring boards of randomized trials: evolving principles and practical suggestions Clinical Investigation. 1: 53-57. DOI: 10.4155/Cli.10.11 |
0.417 |
|
| 2010 |
Cook T, DeMets DL. Review of draft FDA adaptive design guidance. Journal of Biopharmaceutical Statistics. 20: 1132-42. PMID 21058109 DOI: 10.1080/10543406.2010.514455 |
0.355 |
|
| 2010 |
Ellenberg SS, DeMets DL, Fleming TR. Bias and trials stopped early for benefit. Jama. 304: 158; author reply 15. PMID 20628127 DOI: 10.1001/Jama.2010.933 |
0.377 |
|
| 2010 |
Hennekens CH, Hebert PR, Schneider WR, O'Brien P, Demets D, Borer JS. Academic perspectives on the United States Food and Drug Administration's guidance for industry on diabetes mellitus. Contemporary Clinical Trials. 31: 411-3. PMID 20601161 DOI: 10.1016/J.Cct.2010.06.001 |
0.396 |
|
| 2010 |
Friedman LM, Furberg CD, Demets DL. Fundamentals of clinical trials Fundamentals of Clinical Trials. 1-445. DOI: 10.1007/978-1-4419-1586-3 |
0.325 |
|
| 2009 |
Hennekens CH, DeMets D. The need for large-scale randomized evidence without undue emphasis on small trials, meta-analyses, or subgroup analyses. Jama. 302: 2361-2362. PMID 19952322 DOI: 10.1001/Jama.2009.1756 |
0.452 |
|
| 2009 |
Metra M, Eichhorn E, Abraham WT, Linseman J, Böhm M, Corbalan R, DeMets D, De Marco T, Elkayam U, Gerber M, Komajda M, Liu P, Mareev V, Perrone SV, Poole-Wilson P, et al. Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. European Heart Journal. 30: 3015-26. PMID 19700774 DOI: 10.1093/Eurheartj/Ehp338 |
0.354 |
|
| 2009 |
Anand IS, Carson P, Galle E, Song R, Boehmer J, Ghali JK, Jaski B, Lindenfeld J, O'Connor C, Steinberg JS, Leigh J, Yong P, Kosorok MR, Feldman AM, DeMets D, et al. Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial. Circulation. 119: 969-77. PMID 19204305 DOI: 10.1161/Circulationaha.108.793273 |
0.32 |
|
| 2009 |
Lan KKG, DeMets D. Further Comments on the Alpha Spending Function Statistics in Biosciences. 1: 95-111. DOI: 10.1007/S12561-009-9004-3 |
0.394 |
|
| 2008 |
Baron JA, Sandler RS, Bresalier RS, Lanas A, Morton DG, Riddell R, Iverson ER, Demets DL. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet (London, England). 372: 1756-64. PMID 18922570 DOI: 10.1016/S0140-6736(08)61490-7 |
0.385 |
|
| 2007 |
Wittes J, Barrett-Connor E, Braunwald E, Chesney M, Cohen HJ, Demets D, Dunn L, Dwyer J, Heaney RP, Vogel V, Walters L, Yusuf S. Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring Board. Clinical Trials (London, England). 4: 218-34. PMID 17715247 DOI: 10.1177/1740774507079439 |
0.381 |
|
| 2006 |
Demets DL. Futility approaches to interim monitoring by data monitoring committees. Clinical Trials (London, England). 3: 522-9. PMID 17170036 DOI: 10.1177/1740774506073115 |
0.431 |
|
| 2006 |
DeMets DL, Fost N, Powers M. An Institutional Review Board dilemma: responsible for safety monitoring but not in control. Clinical Trials (London, England). 3: 142-8. PMID 16773956 DOI: 10.1191/1740774506Cn137Oa |
0.405 |
|
| 2006 |
Fan X, DeMets DL. Conditional and unconditional confidence intervals following a group sequential test. Journal of Biopharmaceutical Statistics. 16: 107-22. PMID 16440840 DOI: 10.1080/10543400500406595 |
0.718 |
|
| 2006 |
Demets DL, Furberg CD, Friedman LM. Data monitoring in clinical trials: A case studies approach Data Monitoring in Clinical Trials: a Case Studies Approach. 1-374. DOI: 10.1007/0-387-30107-0 |
0.33 |
|
| 2005 |
Lowes BD, Shakar SF, Metra M, Feldman AM, Eichhorn E, Freytag JW, Gerber MJ, Liard JF, Hartman C, Gorczynski R, Evans G, Linseman JV, Stewart J, Robertson AD, Roecker EB, ... Demets DL, et al. Rationale and design of the enoximone clinical trials program. Journal of Cardiac Failure. 11: 659-69. PMID 16360960 DOI: 10.1016/J.Cardfail.2005.10.013 |
0.374 |
|
| 2005 |
Gheorghiade M, Orlandi C, Burnett JC, DeMets D, Grinfeld L, Maggioni A, Swedberg K, Udelson JE, Zannad F, Zimmer C, Konstam MA. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: Outcome study with Tolvaptan (EVEREST) Journal of Cardiac Failure. 11: 260-269. PMID 15880334 DOI: 10.1016/J.Cardfail.2005.03.009 |
0.352 |
|
| 2005 |
Packer M, McMurray J, Massie BM, Caspi A, Charlon V, Cohen-Solal A, Kiowski W, Kostuk W, Krum H, Levine B, Rizzon P, Soler J, Swedberg K, Anderson S, Demets DL. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. Journal of Cardiac Failure. 11: 12-20. PMID 15704058 DOI: 10.1016/J.Cardfail.2004.05.006 |
0.315 |
|
| 2004 |
DeMets D, Califf R, Dixon D, Ellenberg S, Fleming T, Held P, Julian D, Kaplan R, Levine R, Neaton J, Packer M, Pocock S, Rockhold F, Seto B, Siegel J, et al. Issues in regulatory guidelines for data monitoring committees Clinical Trials (London, England). 1: 162-169. PMID 16281888 DOI: 10.1191/1740774504Cn019Xx |
0.397 |
|
| 2004 |
DeMets DL, Fleming TR, Rockhold F, Massie B, Merchant T, Meisel A, Mishkin B, Wittes J, Stump D, Califf R. Liability issues for data monitoring committee members. Clinical Trials (London, England). 1: 525-31. PMID 16279293 DOI: 10.1191/1740774504Cn54Oa |
0.348 |
|
| 2004 |
DeMets DL, Fleming TR. The independent statistician for data monitoring committees. Statistics in Medicine. 23: 1513-7. PMID 15122729 DOI: 10.1002/Sim.1786 |
0.431 |
|
| 2004 |
DeMets DL. Statistical issues in interpreting clinical trials Journal of Internal Medicine. 255: 529-537. PMID 15078496 DOI: 10.1111/J.1365-2796.2004.01320.X |
0.433 |
|
| 2004 |
Chen YH, DeMets DL, Lan KK. Increasing the sample size when the unblinded interim result is promising. Statistics in Medicine. 23: 1023-38. PMID 15057876 DOI: 10.1002/Sim.1688 |
0.527 |
|
| 2004 |
Kosorok MR, Yuanjun S, DeMets DL. Design and analysis of group sequential clinical trials with multiple primary endpoints. Biometrics. 60: 134-45. PMID 15032783 DOI: 10.1111/J.0006-341X.2004.00146.X |
0.4 |
|
| 2003 |
Califf RM, Morse MA, Wittes J, Goodman SN, Nelson DK, DeMets DL, Iafrate RP, Sugarman J. Toward protecting the safety of participants in clinical trials. Controlled Clinical Trials. 24: 256-71. PMID 12757992 DOI: 10.1016/S0197-2456(03)00005-9 |
0.374 |
|
| 2003 |
Chen YH, DeMets DL, Lan KK. Monitoring mortality at interim analyses while testing a composite endpoint at the final analysis. Controlled Clinical Trials. 24: 16-27. PMID 12559639 DOI: 10.1016/S0197-2456(02)00306-9 |
0.559 |
|
| 2002 |
Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 106: 2194-9. PMID 12390947 DOI: 10.1161/01.Cir.0000035653.72855.Bf |
0.304 |
|
| 2002 |
Fleming TR, Ellenberg S, DeMets DL. Monitoring clinical trials: issues and controversies regarding confidentiality. Statistics in Medicine. 21: 2843-51. PMID 12325100 DOI: 10.1002/Sim.1288 |
0.43 |
|
| 2002 |
DeMets DL. Clinical trials in the new millennium. Statistics in Medicine. 21: 2779-87. PMID 12325093 DOI: 10.1002/Sim.1281 |
0.421 |
|
| 2002 |
Califf RM, DeMets DL. Principles from clinical trials relevant to clinical practice: Part II. Circulation. 106: 1172-5. PMID 12196347 DOI: 10.1161/01.Cir.0000023218.39412.32 |
0.392 |
|
| 2002 |
DeMets DL, Califf RM. Lessons learned from recent cardiovascular clinical trials: Part II. Circulation. 106: 880-6. PMID 12176964 DOI: 10.1161/01.Cir.0000023220.26465.89 |
0.376 |
|
| 2002 |
Lee JW, Jo SJ, Demets DL, Kim K. Confidence intervals following group sequential tests in clinical trials with multivariate observations Journal of Statistical Computation and Simulation. 72: 247-259. DOI: 10.1080/00949650212386 |
0.408 |
|
| 2001 |
De Gruttola VG, Clax P, DeMets DL, Downing GJ, Ellenberg SS, Friedman L, Gail MH, Prentice R, Wittes J, Zeger SL. Considerations in the evaluation of surrogate endpoints in clinical trials: Summary of a National Institutes of Health Workshop Controlled Clinical Trials. 22: 485-502. PMID 11578783 DOI: 10.1016/S0197-2456(01)00153-2 |
0.42 |
|
| 2001 |
Wedel H, Demets D, Deedwania P, Fagerberg B, Goldstein S, Gottlieb S, Hjalmarson A, Kjekshus J, Waagstein F, Wikstrand J. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial. American Heart Journal. 142: 502-11. PMID 11526365 DOI: 10.1067/Mhj.2001.117600 |
0.435 |
|
| 2001 |
O'Shea JC, DeMets DL. Statistical issues relating to international differences in clinical trials American Heart Journal. 142: 21-28. PMID 11431652 DOI: 10.1067/Mhj.2001.116275 |
0.395 |
|
| 2001 |
Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL. Effect of carvedilol on survival in severe chronic heart failure New England Journal of Medicine. 344: 1651-1658. PMID 11386263 DOI: 10.1056/Nejm200105313442201 |
0.354 |
|
| 2001 |
Fisher MR, Roecker EB, DeMets DL. The role of an independent statistical analysis center in the Industry-Modified National Institutes of Health Model Drug Information Journal. 35: 115-129. DOI: 10.1177/009286150103500113 |
0.421 |
|
| 2000 |
Spiessens B, Lesaffre E, Verbeke G, Kim K, DeMets DL. An overview of group sequential methods in longitudinal clinical trials Statistical Methods in Medical Research. 9: 497-515. PMID 11191262 DOI: 10.1177/096228020000900506 |
0.406 |
|
| 2000 |
Gong J, Pinheiro JC, Demets DL. Estimating significance level and power comparisons for testing multiple endpoints in clinical trials Controlled Clinical Trials. 21: 313-329. PMID 10913807 DOI: 10.1016/S0197-2456(00)00049-0 |
0.389 |
|
| 2000 |
Reboussin DM, Demets DL, Kim K, Lan KKG. Computations for group sequential boundaries using the Lan-DeMets spending function method Controlled Clinical Trials. 21: 190-207. PMID 10822118 DOI: 10.1016/S0197-2456(00)00057-X |
0.377 |
|
| 2000 |
DeMets DL. Design of phase II trials in congestive heart failure American Heart Journal. 139. PMID 10740134 DOI: 10.1016/S0002-8703(00)90075-9 |
0.328 |
|
| 1999 |
DeMets DL. Statistics and ethics in medical research. Science and Engineering Ethics. 5: 97-117. PMID 11658016 DOI: 10.1007/S11948-999-0059-9 |
0.31 |
|
| 1999 |
DeMets DL, Pocock SJ, Julian DG. The agonising negative trend in monitoring of clinical trials Lancet. 354: 1983-1988. PMID 10622312 DOI: 10.1016/S0140-6736(99)03464-9 |
0.427 |
|
| 1998 |
Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, Gottlieb SO, Mcgrew F, Demets DL, White BG. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure New England Journal of Medicine. 339: 1810-1816. PMID 9854116 DOI: 10.1097/00132586-199910000-00011 |
0.316 |
|
| 1998 |
O'Connor CM, Carson PE, Miller AB, Pressler ML, Belkin RN, Neuberg GW, Frid DJ, Cropp AB, Anderson S, Wertheimer JH, DeMets DL. Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial American Journal of Cardiology. 82: 881-887. PMID 9781971 DOI: 10.1016/S0002-9149(98)00496-2 |
0.325 |
|
| 1998 |
DeMets DL. Sequential Designs in Clinical Trials Cardiac Electrophysiology Review. 2: 57-60. DOI: 10.1023/A:1009954810211 |
0.354 |
|
| 1997 |
DeMets DL. Distinctions between fraud, bias, errors, misunderstanding, and incompetence Controlled Clinical Trials. 18: 637-650. PMID 9408726 DOI: 10.1016/S0197-2456(97)00010-X |
0.381 |
|
| 1997 |
Pinheiro JC, Demets DL. Estimating and reducing bias in group sequential designs with Gaussian independent increment structure Biometrika. 84: 831-845. DOI: 10.1093/Biomet/84.4.831 |
0.304 |
|
| 1996 |
Fleming TR, DeMets DL. Surrogate End Points in Clinical Trials: Are We Being Misled? Annals of Internal Medicine. 125: 605-613. PMID 8815760 DOI: 10.7326/0003-4819-125-7-199610010-00011 |
0.39 |
|
| 1996 |
Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, Demets DL. Effect of amlodipine on morbidity and mortality in severe chronic heart failure New England Journal of Medicine. 335: 1107-1114. PMID 8813041 DOI: 10.1056/Nejm199610103351504 |
0.34 |
|
| 1996 |
Gange SJ, DeMets DL. Sequential monitoring of clinical trials with correlated responses Biometrika. 83: 157-167. DOI: 10.1093/Biomet/83.1.157 |
0.342 |
|
| 1995 |
DeMets DL, Fleming TR, Whitley RJ, Childress JF, Ellenberg SS, Foulkes M, Mayer KH, O'Fallon J, Pollard RB, Rahal JJ, Sande M, Straus S, Walters L, Whitley-Williams P. The Data and Safety Monitoring Board and Acquired immune deficiency syndrome (AIDS) clinical trials Controlled Clinical Trials. 16: 408-421. PMID 8720018 DOI: 10.1016/S0197-2456(95)00073-9 |
0.42 |
|
| 1995 |
Gange SJ, Linton KLP, Scott AJ, DeMets DL, Klein R. A comparison of methods for correlated ordinal measures with ophthalmic applications Statistics in Medicine. 14: 1961-1974. PMID 8677397 DOI: 10.1002/Sim.4780141803 |
0.317 |
|
| 1995 |
Jae Won Lee, DeMets DL. Group sequential comparison of changes: Ad-hoc versus more exact method Biometrics. 51: 21-30. PMID 7766776 DOI: 10.2307/2533311 |
0.33 |
|
| 1995 |
DeMets DL, Lan G. The alpha spending function approach to interim data analyses Cancer Treatment and Research. 75: 1-27. PMID 7640159 DOI: 10.1007/978-1-4615-2009-2_1 |
0.434 |
|
| 1995 |
Fleming TR, Neaton JD, Goldman A, DeMets DL, Launer C, Korvick J, Abrams D. Insights from monitoring the CPCRA didanosine/zalcitabine trial Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 10. PMID 7552519 |
0.307 |
|
| 1994 |
Furberg CD, Julian DG, Bigger JT, Breithardt G, Camm AJ, DeMets DL, Hallstrom A, Janse MJ, Lan KKG, Lazzara R, Marcus FI, Moss AJ, Tijssen JGP, Waldo AL, Pocock SJ, et al. The early termination of clinical trials: Causes, consequences, and control. With special reference to trials in the field of arrhythmias and sudden death Circulation. 89: 2892-2907. PMID 8205706 DOI: 10.1161/01.cir.89.6.2892 |
0.321 |
|
| 1994 |
Schwartz PJ, Furberg CD, Julian DG, Bigger JT, Breithardt G, Camm AJ, DeMets DL, Hallstrom A, Janse MJ, Lan KKG, Lazzara R, Marcus FI, Moss AJ, Tijssen JGP, Waldo AL, et al. The early termination of clinical trials: Causes, consequences, and control European Heart Journal. 15: 721-738. PMID 8088260 |
0.319 |
|
| 1994 |
DeMets DL, Lan KKG. Interim analysis: The alpha spending function approach Statistics in Medicine. 13: 1341-1352. PMID 7973215 DOI: 10.1002/Sim.4780131308 |
0.343 |
|
| 1994 |
Albert JM, Demets DL. On a model-based approach to estimating efficacy in clinical trials Statistics in Medicine. 13: 2323-2335. PMID 7855466 DOI: 10.1002/Sim.4780132204 |
0.37 |
|
| 1994 |
Lan KKG, Reboussin DM, Demets DL. Information and information fractions for design and sequential monitoring of clinical trials Communications in Statistics - Theory and Methods. 23: 403-420. DOI: 10.1080/03610929408831263 |
0.352 |
|
| 1993 |
Fleming TR, DeMets DL. Monitoring of clinical trials: Issues and recommendations Controlled Clinical Trials. 14: 183-197. PMID 8339549 DOI: 10.1016/0197-2456(93)90002-U |
0.434 |
|
| 1992 |
Kim K, Demets DL. Sample size determination for group sequential clinical trials with immediate response Statistics in Medicine. 11: 1391-1399. PMID 1518999 DOI: 10.1002/Sim.4780111012 |
0.365 |
|
| 1992 |
Lee JW, DeMets DL. Sequential rank tests with repeated measurements in clinical trials Journal of the American Statistical Association. 87: 136-142. DOI: 10.1080/01621459.1992.10475184 |
0.301 |
|
| 1991 |
Demets DL, Newcomb PA, Carey P. Design issues for a breast cancer chemoprevention trial Preventive Medicine. 20: 101-108. PMID 2008419 DOI: 10.1016/0091-7435(91)90010-2 |
0.312 |
|
| 1991 |
Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL. Effect of oral milrinone on mortality in severe chronic heart failure New England Journal of Medicine. 325: 1468-1475. PMID 1944425 DOI: 10.1056/Nejm199111213252103 |
0.338 |
|
| 1991 |
Lin DY, Wei LJ, DeMets DL. Exact statistical inference for group sequential trials Biometrics. 47: 1399-1408. PMID 1786325 DOI: 10.2307/2532394 |
0.386 |
|
| 1991 |
Data Monitoring Board of the Physicians' Health Study, Cairns J, Cohen L, Colton T, DeMets DL, Deykin D, Friedman L, Greenwald P, Hutchison GB, Rosner B. Issues in the early termination of the aspirin component of the physicians' health study Annals of Epidemiology. 1: 395-405. PMID 1669520 DOI: 10.1016/1047-2797(91)90009-2 |
0.346 |
|
| 1991 |
Lee JW, DeMets DL. Sequential comparison of changes with repeated measurements data Journal of the American Statistical Association. 86: 757-762. DOI: 10.1080/01621459.1991.10475106 |
0.31 |
|
| 1990 |
Halperin M, DeMets DL, Ware JH. Early methodological developments for clinical trials at the National Heart, Lung and Blood Institute Statistics in Medicine. 9: 881-892. PMID 2218191 DOI: 10.1002/Sim.4780090804 |
0.434 |
|
| 1989 |
Lan KKG, DeMets DL. Changing frequency of interim analysis in sequential monitoring Biometrics. 45: 1017-1020. PMID 2790114 DOI: 10.2307/2531701 |
0.316 |
|
| 1987 |
Demets DL. Methods for combining randomized clinical trials: Strengths and limitations Statistics in Medicine. 6: 341-348. PMID 3616287 DOI: 10.1002/Sim.4780060325 |
0.404 |
|
| 1987 |
Williams GW, Snedecor SM, DeMets DL. Recruitment experience in the nocturnal oxygen therapy trial Controlled Clinical Trials. 8: 121-130. PMID 3440385 DOI: 10.1016/0197-2456(87)90015-8 |
0.37 |
|
| 1987 |
Kim K, DeMets DL. Confidence intervals following group sequential tests in clinical trials Biometrics. 43: 857-864. PMID 3427170 DOI: 10.2307/2531539 |
0.318 |
|
| 1987 |
Demets DL. Practical aspects in data monitoring: a brief review Statistics in Medicine. 6: 753-760. PMID 3321314 DOI: 10.1002/Sim.4780060706 |
0.433 |
|
| 1987 |
George SL, Friedman LM, Furberg CD, Demets DL. Fundamentals of Clinical Trials. (2nd ed.). Journal of the American Statistical Association. 82: 358. DOI: 10.2307/2289197 |
0.386 |
|
| 1987 |
Kim K, Demets DL. Design and analysis of group sequential tests based on the type I error spending rate function Biometrika. 74: 149-154. DOI: 10.1093/Biomet/74.1.149 |
0.312 |
|
| 1985 |
DeMets DL. Randomised controlled clinical trials: C.J. Bulpitt Martinus Nijhoff Publishers, The Hague, 1983, 261 pp., $52.00 Controlled Clinical Trials. 6: 244-245. DOI: 10.1016/0197-2456(85)90088-1 |
0.352 |
|
| 1984 |
Demets DL. Can early stopping procedures impact significantly on the efficiency of clinical trials without serious loss of information? Statistics in Medicine. 3: 445-451. PMID 6528138 DOI: 10.1002/Sim.4780030426 |
0.342 |
|
| 1984 |
DeMets DL, Hardy R, Friedman LM, Gordon Lan KK. Statistical aspects of early termination in the beta-blocker heart attack trial Controlled Clinical Trials. 5: 362-372. PMID 6151482 DOI: 10.1016/S0197-2456(84)80015-X |
0.428 |
|
| 1984 |
DeMets DL. Stopping Guidelines Vs Stopping Rules: A Practitioner'S Point of View Communications in Statistics - Theory and Methods. 13: 2395-2417. DOI: 10.1080/03610928408828833 |
0.374 |
|
| 1984 |
DeMets DL, Gordon Lan KK. An overview of sequential methods and their application in clinical trials Communications in Statistics - Theory and Methods. 13: 2315-2338. DOI: 10.1080/03610928408828829 |
0.317 |
|
| 1982 |
Halperin M, Lan KK, Ware JH, Johnson NJ, DeMets DL. An aid to data monitoring in long-term clinical trials. Controlled Clinical Trials. 3: 311-23. PMID 7160189 DOI: 10.1016/0197-2456(82)90022-8 |
0.409 |
|
| 1982 |
Demets DL, Ware JH. Asymmetric group sequential boundaries for monitoring clinical trials Biometrika. 69: 661-663. DOI: 10.1093/Biomet/69.3.661 |
0.372 |
|
| 1982 |
DeMets D, Hardy R, Friedman L, Lan G. Aspects of early termination in the beta-blocker heart attack trial Controlled Clinical Trials. 3: 135. DOI: 10.1016/0197-2456(82)90041-1 |
0.317 |
|
| 1981 |
May GS, DeMets DL, Friedman LM, Furberg C, Passamani E. The randomized clinical trial: Bias in analysis Circulation. 64: 669-673. PMID 7023743 DOI: 10.1161/01.Cir.64.4.669 |
0.441 |
|
| 1981 |
Howard JM, DeMets D. How informed is informed consent?: The BHAT experience Controlled Clinical Trials. 2: 287-303. PMID 6120794 DOI: 10.1016/0197-2456(81)90019-2 |
0.34 |
|
| 1981 |
Friedman L, DeMets D. The data monitoring committee: how it operates and why. Irb: Ethics & Human Research. 3: 6-8. DOI: 10.2307/3563613 |
0.37 |
|
| 1980 |
Wu M, Fisher M, DeMets D. Sample sizes for long-term medical trial with time-dependent dropout and event rates Controlled Clinical Trials. 1: 111-124. PMID 7261605 DOI: 10.1016/0197-2456(80)90014-8 |
0.354 |
|
| 1980 |
Demets DL, Ware JH. Group sequential methods for clinical trials with a one-sided hypothesis Biometrika. 67: 651-660. DOI: 10.1093/Biomet/67.3.651 |
0.404 |
|
| 1976 |
Henkin RI, Schecter PJ, Friedewald WT, Demets DL, Raff M. A double blind study of the effects of zinc sulfate on taste and smell dysfunction American Journal of the Medical Sciences. 272: 285-299. PMID 797259 DOI: 10.1097/00000441-197611000-00006 |
0.301 |
|
| 1976 |
Byar DP, Simon RM, Friedewald WT, Schlesselman JJ, DeMets DL, Ellenberg JH, Gail MH, Ware JH. Randomized clinical trials. Perspectives on some recent ideas New England Journal of Medicine. 295: 74-80. PMID 775331 DOI: 10.1056/Nejm197607082950204 |
0.433 |
|
| Show low-probability matches. |